4-(6-氯-3-哒嗪)-苯甲酸 | 845827-17-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-(6-氯-3-哒嗪)-苯甲酸
• 英文名称: 4-(6-chloro-pyridazin-3-yl)-benzoic acid
• 英文别名: 4-(6-chloro-3-pyridazinyl)benzenecarboxylic acid；4-(6-chloropyridazin-3-yl)benzoic Acid
• CAS: 845827-17-0
• 化学式: C₁₁H₇ClN₂O₂
• 分子量: 234.642
• InChiKey: KFIYDCWKTZPYHH-UHFFFAOYSA-N

物化性质

• 沸点：
  493.9±35.0 °C(Predicted)
• 密度：
  1.416±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-(6-氯-3-哒嗪)-苯甲酸 在 氯化亚砜 作用下， 生成 4-(6-chloro-pyridazin-3-yl)-benzoyl chloride
  参考文献：
  名称：

  WO2007/126957

  摘要：

  公开号：

文献信息

• NEW COMPOUNDS
  申请人：Serrano-Wu Michael H.

  公开号：US20090247534A1

  公开（公告）日：2009-10-01

  The present invention provides organic compounds of the following structure; A-L1-B-C-D-L2-E that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.

  本发明提供了具有以下结构的有机化合物；A-L1-B-C-D-L2-E，其可用于治疗或预防与动物中DGAT1活性相关的疾病或疾病，特别是人类。
• Imidazopyridine Derivatives
  申请人：Kishino Hiroyuki

  公开号：US20080200494A1

  公开（公告）日：2008-08-21

  The invention provides imidazopyridine derivatives represented by the general formula [I] [in which R 1 and R 2 may be the same or different and stand for C 1-6 alkyl or the like, R 3 and R 4 stand for hydrogen atom, methyl group or the like, W stands for mono- or bi-cyclic 3- to 8-membered aromatic or aliphatic heterocycle or the like, and Ar stands for optionally substituted aromatic heterocycle or the like]. These compounds act as melanin-concentrating hormone receptor antagonist and are useful as medicines for central nervous system disorders, cardiovascular system disorders and metabolic disorders.

  该发明提供了由通式[I]表示的咪唑吡啶衍生物 [其中R1和R2可能相同或不同，且代表C1-6烷基或类似物，R3和R4代表氢原子，甲基基团或类似物，W代表单环或双环的3-8元芳香或脂肪杂环或类似物，Ar代表可选择取代的芳香杂环或类似物]。这些化合物作为黑色素浓集激素受体拮抗剂，可用于治疗中枢神经系统疾病、心血管系统疾病和代谢性疾病的药物。
• Imidazopyridine derivatives
  申请人：Banyu Pharmaceuticals, Co., Ltd.

  公开号：US07504412B2

  公开（公告）日：2009-03-17

  The invention provides imidazopyridine derivatives represented by the general formula [I] [in which R1 and R2 may be the same or different and stand for C1-6 alkyl or the like, R3 and R4 stand for hydrogen atom, methyl group or the like, W stands for mono- or bi-cyclic 3- to 8-membered aromatic or aliphatic heterocycle or the like, and Ar stands for optionally substituted aromatic heterocycle or the like]. These compounds act as melanin-concentrating hormone receptor antagonist and are useful as medicines for central nervous system disorders, cardiovascular system disorders and metabolic disorders.

  本发明提供了由通式[I]表示的咪唑吡啶衍生物 [其中R1和R2可以相同或不同，代表C1-6烷基或类似物，R3和R4代表氢原子，甲基基团或类似物，W代表单环或双环3-8成员的芳香或脂肪族杂环或类似物，Ar代表可选取代的芳香杂环或类似物]。这些化合物作为黑素浓聚激素受体拮抗剂，并且可用于治疗中枢神经系统疾病、心血管系统疾病和代谢性疾病的药物。
• IMIDAZOPYRIDINE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1657242A1

  公开（公告）日：2006-05-17

  The invention provides imidazopyridine derivatives represented by the general formula [I] [in which R1 and R2 may be the same or different and stand for C1-6 alkyl or the like, R3 and R4 stand for hydrogen atom, methyl group or the like, W stands for mono- or bi-cyclic 3- to 8-membered aromatic or aliphatic heterocycle or the like, and Ar stands for optionally substituted aromatic heterocycle or the like]. These compounds act as melanin-concentrating hormone receptor antagonist and are useful as medicines for central nervous system disorders, cardiovascular system disorders and metabolic disorders.

  本发明提供由通式[I]代表的咪唑吡啶衍生物[其中 R1 和 R2 可以相同或不同，代表 C1-6 烷基或类似物，R3 和 R4 代表氢原子、甲基或类似物，W 代表单环或双环 3 至 8 元芳香族或脂肪族杂环或类似物，Ar 代表任选取代的芳香族杂环或类似物]。这些化合物具有黑色素浓缩激素受体拮抗剂的作用，可作为治疗中枢神经系统疾病、心血管系统疾病和代谢紊乱的药物。
• New compounds
  申请人：Novartis AG

  公开号：EP2301923A1

  公开（公告）日：2011-03-30

  The present invention provides new organic compounds of the following formula:         A-L1-B-C-D-L2-E wherein A, L1, B, C, D, L2 and E are as defined in the description of the invention, that are useful for treating or preventing conditions or disorders associated with DGAT1 activity, particularly type 2 diabetes, and pharmaceutical compositions comprising such compounds.

  本发明提供了下式的新型有机化合物： A-L1-B-C-D-L2-E 其中A、L1、B、C、D、L2和E如本发明描述中所定义，可用于治疗或预防与DGAT1活性相关的病症或紊乱，尤其是2型糖尿病，以及包含此类化合物的药物组合物。